Company Prestige BioPharma Limited

A950210

KR8702070002

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Annual profits - Rate of surprise

Sector Biopharmaceuticals

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-13 EDT			5-day change	1st Jan Change
7,980 ^KRW	0.00%		-1.48%	-15.82%

2023	Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer	CI
2023	Prestige BioPharma Limited Develops First-In-Class PAUF-detecting Diagnostic Kit	CI

Prestige Biopharma Ltd is a Singapore-based biopharmaceutical company. The Company is focused on the development of biosimilars and antibody drugs as well as vaccines for infectious diseases. Its biosimilar portfolio consists of over 12 pipelines, including HD201 (trastuzumab) in Phase III, HD204 (bevacizumab) in Phase III, and PBP1502 (adalimumab) in Phase I. Its antibody therapeutic portfolio includes PBP1510, PBP1710, IDC001, IDC005, IDC007, IDC008 and others. PBP1510 specifically binds pancreatic adenocarcinoma upregulated factor (PAUF), a protein that drives cancer cells to spread through blood flow and to escape immune recognition and exerts anti-metastasis and immune modulation effects. PBP1710 specifically binds to collagen triple helix repeat containing 1 (CTHRC1), a protein that facilitates cancer cells and exerts anti-metastasis and anti-tumor growth effects. IDC001 is designed to treat cancers that express high level of PAUF and CTHRC1.

KRW in Million	2022	Weight	2023	Weight	Delta
Anti-cancer Drugs 100.0 %	0	nan %	162	100.0 %	-

KRW in Million	2022	Weight	2023	Weight	Delta
Singapore 100.0 %	0	nan %	162	100.0 %	-

Managers	Title	Age	Since
So-Yeon Park CEO	Chief Executive Officer	61	-
Lai Wat Tay DFI	Director of Finance/CFO	68	-
Jin Woo Kim COO	Chief Operating Officer	60	-

Members of the board	Title	Age	Since
Lai Wat Tay DFI	Director of Finance/CFO	68	-
So-Yeon Park CEO	Chief Executive Officer	61	-
Eui-Kyung Lee BRD	Director/Board Member	65	-
Jin Woo Kim COO	Chief Operating Officer	60	-
Seung Joo Oh BRD	Director/Board Member	48	-
Kue Ho Bang BRD	Director/Board Member	61	23-06-14
Kok Fatt Lee BRD	Director/Board Member	51	-
Kyung Hee Jeon BRD	Director/Board Member	56	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	12,019,231	0	0	-

Name	Equities	%	Valuation
Mayson Partners Pte Ltd. 21.65 %	13,010,370	21.65 %	76 M ₩
Octava Fund Ltd. 16.04 %	9,638,935	16.04 %	56 M ₩
So-yun Park 15.40 %	9,256,280	15.40 %	54 M ₩
Jin-woo Kim 14.94 %	8,978,600	14.94 %	52 M ₩
Octava Pte Ltd. 2.080 %	1,250,000	2.080 %	7 M ₩
Tin Yong Tan 0.0499 %	30,000	0.0499 %	174 951 ₩

Name	Equities	%	Valuation
PRESTIGE BIOLOGICS CO., LTD. 24.73%	15,206,560	24.73%	45,330,299 $

Prestige BioPharma Ltd.

04-24/28 Nucleos South Building 21 Biopolis Road

138567, Singapore

http://www.prestigebiopharma.com

address Prestige BioPharma Limited(A950210)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
PRESTIGE BIOPHARMA LIMITED	-15.82%	70.29M
CSL LIMITED	-1.26%	89.46B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.74B
BIOGEN INC.	-12.32%	33.03B
UCB	+54.18%	24.68B
BIOMARIN PHARMACEUTICAL INC.	-17.39%	15.12B
INCYTE CORPORATION	-9.14%	12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.48%	11.79B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.45%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+6.97%	8.9B

Biopharmaceuticals